Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
ABBVIE INC.
Gilead Sciences Inc
Vertex Pharmaceuticals Inc
Merck & Co., Inc.
AstraZeneca PLC
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Pfizer Inc.
Moderna, Inc. Common Stock
Johnson & Johnson
The chart shows the growth of an initial investment of $10,000 in Amgen Inc, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Amgen Inc (AMGN) has returned 5.83% so far this year and 20.94% over the past 12 months. Looking at the last ten years, AMGN has achieved an annualized return of 8.49%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Amgen Inc (AMGN) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.99% | 14.34% | -9.32% | -1.96% | ||||||||
| 2025 | 8.86% | 7.37% | 1.37% | -6.33% | 0.40% | -2.25% | 5.39% | -3.15% | -1.84% | 4.91% | 15.76% | -4.59% |
| 2024 | 9.39% | -12.93% | 2.83% | -2.90% | 11.55% | 1.84% | 6.11% | -0.67% | -2.92% | -0.59% | -11.24% | -7.60% |
| 2023 | -3.25% | -7.02% | 4.94% | -0.93% | -8.07% | 0.94% | 5.85% | 9.11% | 3.90% | -4.49% | 5.22% | 6.69% |
| 2022 | 1.57% | -0.29% | 7.34% | -4.05% | 10.01% | -5.65% | 1.73% | -2.85% | -6.52% | 18.43% | 6.23% | -8.81% |
| 2021 | 4.40% | -7.93% | 10.15% | -4.04% | -1.13% | 0.64% | -0.90% | -6.85% | -5.72% | -3.10% | -4.38% | 12.24% |
| 2020 | -11.09% | -7.70% | 1.42% | 21.09% | -1.42% | 3.05% | 3.89% | 3.46% | 1.64% | -14.95% | 0.22% | 2.24% |
| 2019 | -2.81% | 1.91% | -0.74% | -6.18% | -4.96% | 7.14% | -0.16% | 11.92% | -6.65% | 10.73% | 9.55% | 2.78% |
| 2018 | 6.10% | -0.66% | -7.45% | 2.68% | 4.34% | 2.12% | 6.77% | 1.77% | 4.04% | -7.19% | 8.01% | -6.45% |
| 2017 | 5.97% | 11.31% | -7.83% | -0.80% | -5.16% | 10.83% | 1.09% | 1.69% | 4.66% | -6.31% | 0.21% | -0.15% |
| 2016 | 5.52% | -0.42% | -3.46% | 12.86% | -1.65% | -2.19% | -14.99% | 2.05% | 1.37% |
The charts below present risk-adjusted performance metrics for Amgen Inc (AMGN) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of AMGN compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Amgen Inc volatility is 1.30%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 90.59B | 97.15B | 65.12B | 61.17B | 62.95B | 59.71B | 66.42B | 79.95B | 77.63B | 71.58B | 69.01B | 66.13B | 54.30B | 48.87B | 43.49B | 39.63B |
| Equity Attributable To Parent (USD) | 8.66B | 6.23B | 3.66B | 6.70B | 9.41B | 9.67B | 12.50B | 25.24B | 29.88B | 28.08B | 25.78B | 22.10B | 19.06B | 19.03B | 23.94B | 22.67B |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 8.66B | 6.23B | 3.66B | 6.70B | 9.41B | 9.67B | 12.50B | 25.24B | 29.88B | 28.08B | 25.78B | 22.10B | 19.06B | 19.03B | 23.94B | 22.67B |
| Other Non-current Liabilities (USD) | 1.84B | 7.92B | 6.83B | 8.97B | 8.90B | 7.30B | 6.53B | 10.39B | 1.95B | 3.27B | 5.51B | 3.95B | 518.00M | 2.66B | - | - |
| Long-term Debt (USD) | 54.60B | 64.61B | 38.95B | 33.31B | 32.99B | 29.90B | 33.90B | 35.30B | 34.60B | 31.56B | 30.72B | 32.13B | 26.53B | 21.43B | 13.36B | - |
| Noncurrent Liabilities (USD) | 56.44B | 72.53B | 45.77B | 42.28B | 41.89B | 37.20B | 40.43B | 45.69B | 36.55B | 34.83B | 36.22B | 36.08B | 27.05B | 24.09B | 12.97B | 13.09B |
| Other Current Liabilities (USD) | 21.69B | 15.42B | 13.02B | 9.74B | 9.13B | 10.48B | 11.28B | 6.85B | 9.37B | 6.79B | 4.88B | 6.16B | 6.28B | 4.20B | 5.09B | 3.30B |
| Wages (USD) | 1.44B | 1.38B | 1.10B | 1.08B | 1.10B | 981.00M | 1.00B | 816.00M | 920.00M | 916.00M | 920.00M | 1.00B | 1.01B | 916.00M | 764.00M | - |
| Accounts Payable (USD) | 2.37B | 1.59B | 1.57B | 1.37B | 1.42B | 1.37B | 1.21B | 1.35B | 917.00M | 965.00M | 1.21B | 787.00M | 905.00M | 642.00M | 716.00M | 574.00M |
| Current Liabilities (USD) | 25.49B | 18.39B | 15.69B | 12.18B | 11.65B | 12.84B | 13.49B | 9.02B | 11.20B | 8.67B | 7.01B | 7.95B | 8.19B | 5.75B | 6.57B | 3.87B |
| Liabilities (USD) | 81.93B | 90.92B | 61.46B | 54.47B | 53.54B | 50.03B | 53.92B | 54.71B | 47.75B | 43.49B | 43.23B | 44.03B | 35.24B | 29.84B | 19.54B | 16.96B |
| Other Non-current Assets (USD) | 31.34B | 28.24B | 21.43B | 21.41B | 20.33B | 16.93B | 16.40B | 16.88B | 16.38B | 16.51B | 16.38B | 20.15B | 13.80B | 13.27B | 14.84B | 14.96B |
| Intangible Assets (USD) | 22.28B | 32.64B | 16.08B | 15.18B | 16.59B | 19.41B | 7.44B | 8.61B | 10.28B | 11.64B | 12.69B | 13.26B | 3.97B | 2.58B | - | - |
| Fixed Assets (USD) | 7.91B | 5.94B | 5.43B | 5.18B | 4.89B | 4.93B | 4.96B | 4.99B | 4.96B | 4.91B | 5.22B | 5.35B | 5.33B | 5.42B | 5.52B | 5.74B |
| Noncurrent Assets (USD) | 61.53B | 66.82B | 42.94B | 41.78B | 41.80B | 41.27B | 28.80B | 30.48B | 31.62B | 33.06B | 34.30B | 38.76B | 23.09B | 21.28B | 20.36B | 20.70B |
| Other Current Assets (USD) | 22.83B | 20.81B | 17.26B | 15.30B | 17.25B | 14.86B | 34.68B | 46.64B | 43.27B | 36.08B | 32.07B | 24.35B | 28.47B | 25.11B | 21.11B | 16.71B |
| Inventory (USD) | 6.23B | 9.52B | 4.93B | 4.09B | 3.89B | 3.58B | 2.94B | 2.83B | 2.75B | 2.44B | 2.65B | 3.02B | 2.74B | 2.48B | 2.02B | 2.22B |
| Current Assets (USD) | 29.06B | 30.33B | 22.19B | 19.39B | 21.14B | 18.44B | 37.62B | 49.48B | 46.01B | 38.52B | 34.71B | 27.37B | 31.21B | 27.59B | 23.13B | 18.93B |
| Assets (USD) | 90.59B | 97.15B | 65.12B | 61.17B | 62.95B | 59.71B | 66.42B | 79.95B | 77.63B | 71.58B | 69.01B | 66.13B | 54.30B | 48.87B | 43.49B | 39.63B |
As tech stocks decline and recession fears grow, investors are rotating into defensive healthcare stocks. AbbVie and Amgen are recommended as stable dividend-paying pharmaceutical companies with strong product portfolios and reliable dividend histories that can weather economic downturns.
U.S. stock markets opened sharply lower on April 2, 2026, amid Iran conflict concerns and Tesla's disappointing delivery report, but recovered to near breakeven by midday. Oil prices surged 10% following Trump's Wednesday address, though reports of Iran-Oman negotiations on Strait of Hormuz traffic helped stabilize stocks. Tesla's first-quarter deliveries fell short of expectations, while healthcare stocks declined on tariff concerns.
The Trump administration is preparing to announce 100% tariffs on pharmaceutical companies that haven't secured pricing deals with the White House, potentially as soon as Thursday. The tariffs stem from a Section 232 investigation citing national security grounds. Major drugmakers including Pfizer, Eli Lilly, AstraZeneca, Novo Nordisk, and Johnson & Johnson have already secured three-year reprieves by agreeing to most-favored-nation pricing. The tariff threat is part of a broader pricing strategy that includes the TrumpRx.gov platform for comparing discounted drug prices.
Ardelyx, Inc. announced the appointment of Dr. Rajani Dinavahi as Chief Medical Officer. Dr. Dinavahi brings over two decades of healthcare and biotechnology experience, including leadership roles at Atara Biotherapeutics and Amgen. She will lead medical capabilities and pipeline advancement for the commercial-stage biopharmaceutical company.
Teva Pharmaceutical announced FDA approval of PONLIMSI (denosumab-adet), a biosimilar to Prolia for treating various bone diseases, and acceptance of regulatory filings for its omalizumab biosimilar candidate to Xolair by both FDA and EMA. These approvals represent significant progress in Teva's 'Pivot to Growth' strategy to expand its biosimilar portfolio.
Teva Pharmaceutical announced FDA approval of PONLIMSI (denosumab-adet) biosimilar for treating various bone diseases, and acceptance of regulatory filings for an omalizumab biosimilar candidate by both FDA and EMA. These milestones represent significant progress in Teva's 'Pivot to Growth' strategy to establish itself as a leading biopharmaceutical company with a competitive biosimilar portfolio.
Teva Pharmaceutical announced FDA approval of PONLIMSI (denosumab-adet), a biosimilar to Prolia for treating osteoporosis and related bone conditions across all indications. Additionally, the company's proposed biosimilar candidate to Xolair (omalizumab) for allergic asthma and other conditions received filing acceptance from both the U.S. FDA and European EMA. These milestones advance Teva's Pivot to Growth strategy and expand its biosimilars portfolio.
The Schwab U.S. Dividend Equity ETF (SCHD) completed its annual reconstitution, adding UnitedHealth and Abbott Laboratories while removing AbbVie. These changes increased the fund's healthcare sector allocation from 15.4% to 18.9%, making it the second-largest sector weighting. The new holdings have a higher average dividend growth rate (9.4% vs 8.6%), which should generate more income and potentially higher total returns for investors over time.
SK pharmteco announced it will host a one-day scientific symposium on April 8th in Cambridge, Massachusetts focused on continuous manufacturing, advanced processing, and scalable technologies in pharmaceutical production. The event will feature keynote speakers and expert panels from leading organizations including Gilead, Antheia, Eli Lilly, and Amgen to discuss the future of pharmaceutical manufacturing.
Abivax and Nektar Therapeutics are clinical-stage biotech companies with promising drug candidates that could make them attractive acquisition targets. Abivax is developing obefazimod for inflammatory diseases with phase 3 trial data expected in Q2, while Nektar's rezpegaldesleukin shows strong potential for eczema treatment. Both companies have sufficient funding and could be acquired by major pharmaceutical companies at premium valuations.